FDA Releases Guidance to Improve Pulse Oximeter Accuracy Across Skin Tones
The Food and Drug Administration (FDA) has recently released long-awaited guidance aimed at improving the accuracy of pulse oximeters for individuals with all skin tones. This significant step follows years of concerns that these devices, which measure blood oxygen levels, may provide inaccurate readings for people with darker skin.
Key Takeaways from the New FDA Guidance:
- Expanded Testing Requirements: The guidance recommends a substantial increase in the number of data points for testing, from 200 to 3,000.
- Diverse Testing Populations: The FDA emphasizes the importance of testing pulse oximeters on diverse populations, with a specific focus on including individuals with a wide range of skin tones.
- Increased Sample Sizes: The recommended sample size for studies has been significantly increased from 10 people to 150 or more.
Why is this important for APPs?
Pulse oximeters are a crucial tool in the assessment and management of many pulmonary conditions. Inaccurate readings can lead to:
- Misdiagnosis and Delayed Treatment: Incorrect oxygen saturation levels can mask serious conditions, such as hypoxemia, and delay necessary interventions.
- Unnecessary Interventions: Conversely, inaccurate readings can lead to unnecessary interventions, such as supplemental oxygen therapy, which may have potential side effects.
- Health Disparities: The potential for inaccurate readings in individuals with darker skin tones can contribute to health disparities and inequities in healthcare.
What can APPs do?
- Stay Informed: Familiarize yourself with the FDA’s new guidance and its implications for clinical practice.
- Advocate for Diverse Testing: Encourage manufacturers to adhere to the new guidelines and prioritize the inclusion of diverse populations in their testing protocols.
- Educate Patients: Educate patients about the potential limitations of pulse oximetry, particularly in individuals with darker skin tones.
- Utilize Clinical Judgment: Always consider pulse oximetry readings in conjunction with clinical findings and other relevant factors when making clinical decisions.
The FDA’s new guidance represents a crucial step towards ensuring the accuracy and equitable use of pulse oximeters across all populations. By staying informed and advocating for change, APPs can play a vital role in improving patient care and reducing health disparities.
You can find the full article from STAT+ HERE.
Have pulmonary research you want to share with our members? Reach out to APAPP at
